Patents by Inventor Robertus Cornelis ROOVERS

Robertus Cornelis ROOVERS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES THAT BIND CD123 AND GAMMA-DELTA T CELL RECEPTORS
    Publication number: 20240141071
    Abstract: The present invention relates to antibodies capable of binding human CD123 and capable of binding the V?2 chain of a human V?9V?2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.
    Type: Application
    Filed: February 28, 2022
    Publication date: May 2, 2024
    Inventors: Robertus Cornelis ROOVERS, Johannes Jelle VAN DER VLIET, David LUTJE HULSIK, Paul Willem Henri Ida PARREN, Jurjen Matthijs RUBEN, Charlotte Merette MOUSSET
  • ANTIBODIES THAT BIND EGFR AND ERBB3
    Publication number: 20240052043
    Abstract: The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 pM for inhibiting EGFR and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC3-luc2 cells. Further described are method for producing the bispecific antibodies and means and methods for the treatment of subjects with the antibodies.
    Type: Application
    Filed: October 2, 2023
    Publication date: February 15, 2024
    Inventors: Ton LOGTENBERG, Mark THROSBY, Robertus Cornelis ROOVERS
  • Methods of treating a subject having an EGFR-positive and/or ErbB-3-positive tumor
    Patent number: 11820825
    Abstract: The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 pM for inhibiting EGFR and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC3-luc2 cells. Further described are method for producing the bispecific antibodies and means and methods for the treatment of subjects with the antibodies.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: November 21, 2023
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robertus Cornelis Roovers
  • Antibodies that bind EGFR and cMET
    Patent number: 11773170
    Abstract: The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full length antibody. In some embodiments the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some embodiment the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: October 3, 2023
    Inventors: Cecilia Anna Wilhelmina Geuijen, Robertus Cornelis Roovers, Mark Throsby, Cornelis Adriaan De Kruif, Ton Logtenberg
  • ANTIBODIES THAT BIND GAMMA-DELTA T CELL RECEPTORS
    Publication number: 20230303694
    Abstract: The present invention relates to antibodies capable of binding a human V?9V?d2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.
    Type: Application
    Filed: June 9, 2023
    Publication date: September 28, 2023
    Inventors: Paul Willem Henri Ida PARREN, Robertus Cornelis ROOVERS, Johannes Jelle VAN DER VLIET, David LUTJE HULSIK, Peter Alexander Gerardus Maria MACHIELSEN, Michiel VAN WESTERHOVEN, Lisa Anna KING, Felix-Lennart FENNEMANN
  • ANTIBODIES THAT BIND PSMA AND GAMMA-DELTA T CELL RECEPTORS
    Publication number: 20230272110
    Abstract: Provided herein are antibodies capable of binding human PSMA and capable of binding a human V?9V?2 T cell receptor. In particular, provided herein are pharmaceutical compositions comprising the antibodies capable of binding human PSMA and capable of binding a human V?9V? T cell receptor and uses of the antibodies for medical treatment.
    Type: Application
    Filed: July 8, 2021
    Publication date: August 31, 2023
    Inventors: Robertus Cornelis Roovers, Johannes Jelle VAN DER VLIET, Lisa Anna KING, Paul Willem Henri Ida PARREN, Victoria IGLESIAS GUIMARAIS, David LUTJE HULSIK, Peter Alexander Gerardus Maria MACHIELSEN
  • TREATMENT OF CANCER COMPRISING ADMINISTRATION OF Vg9Vd2 T CELL RECEPTOR BINDING ANTIBODIES
    Publication number: 20230036284
    Abstract: The invention relates to methods for the treatment of cancer. In particular, the invention relates to methods for the treatment of cancer, comprising administration of a high dose of an antibody capable of binding a human V?9V?2 T cell receptor.
    Type: Application
    Filed: September 16, 2020
    Publication date: February 2, 2023
    Inventors: Robertus Cornelis Roovers, Gerard Joseph Maria Jean Horbach, Thilo Alexander Riedl, Johannes Jelle Van Der Vliet, Paul Willem Henri Ida Parren
  • BISPECIFIC ANTIBODY
    Publication number: 20220185885
    Abstract: An agent for preventing, suppressing the progression of symptoms of, suppressing the recurrence of or treating autoimmune diseases, comprising a bispecific antibody or an antibody fragment thereof, having a first arm specifically binding to PD-1 and a second arm specifically binding to CD19, as described herein.
    Type: Application
    Filed: April 3, 2020
    Publication date: June 16, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shiro SHIBAYAMA, Tomoya TEZUKA, Mark THROSBY, Cornelis Adriaan DE KRUIF, Pieter Fokko VAN LOO, Rinse KLOOSTER, Robertus Cornelis ROOVERS
  • ANTIBODIES THAT BIND EGFR AND ERBB3
    Publication number: 20210155698
    Abstract: The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 p M for inhibiting EGER and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC 3-luc2 cells. Further described are method for producing the bispecific antibodies and means and methods for the treatment of subjects with the antibodies.
    Type: Application
    Filed: October 21, 2020
    Publication date: May 27, 2021
    Applicant: Merus N.V.
    Inventors: Ton LOGTENBERG, Mark Throsby, Robertus Cornelis Roovers
  • Antibodies that bind EGFR and ErbB3
    Patent number: 10844127
    Abstract: The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 pM for inhibiting EGFR and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC3-luc2 cells. Further described are method for producing the bispecific antibodies and means and methods for the treatment of subjects with the antibodies.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: November 24, 2020
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robertus Cornelis Roovers
  • ANTIBODIES THAT BIND EGFR AND CMET
    Publication number: 20200247892
    Abstract: The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibody may comprise a common light chain, it may be a human antibody. The antibody may be a full length antibody. In some embodiments the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some embodiment the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.
    Type: Application
    Filed: August 9, 2018
    Publication date: August 6, 2020
    Inventors: Cecilia Anna Wilhelmina GEUIJEN, Robertus Cornelis ROOVERS, Mark THROSBY, Cornelis Adriaan De Kruif, Ton Logtenberg
  • ANTIBODIES THAT BIND EGFR AND ERBB3
    Publication number: 20170058035
    Abstract: The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 pM for inhibiting EGFR and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC3-luc2 cells. Further described are method for producing the bispecific antibodies and means and methods for the treatment of subjects with the antibodies.
    Type: Application
    Filed: February 27, 2015
    Publication date: March 2, 2017
    Applicant: MERUS N.V.
    Inventors: Ton LOGTENBERG, Mark THROSBY, Robertus Cornelis ROOVERS